Aya Shiba‐Ishii

Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer

Aya Shiba‐Ishii, Ted W. Johnson, Ibiayi Dagogo‐Jack et al. · Nature Cancer · 2022 · 63 citations · Full text

Oncology, Medicine, Molecular Biology +9

Stratifin accelerates progression of lung adenocarcinoma at an early stage

Aya Shiba‐Ishii, Yunjung Kim, Toshihiro Shiozawa et al. · Molecular Cancer · 2015 · 52 citations · Full text

High expression of stratifin is a universal abnormality during the course of malignant progression of early‐stage lung adenocarcinoma

Aya Shiba‐Ishii, Junko Kano, Yukio Morishita et al. · International Journal of Cancer · 2011 · 50 citations · Full text

Inflammatory Lung Disease, Lung Adenocarcinoma, Pathology +20

Aberrant Stratifin Overexpression Is Regulated by Tumor-Associated CpG Demethylation in Lung Adenocarcinoma

Aya Shiba‐Ishii, Masayuki Noguchi · American Journal Of Pathology · 2012 · 49 citations · Full text

Tumor-associated Cpg Demethylation, Oncogenic Agent, Medicine +10

Stratifin regulates stabilization of receptor tyrosine kinases via interaction with ubiquitin-specific protease 8 in lung adenocarcinoma

Yunjung Kim, Aya Shiba‐Ishii, Tomoki Nakagawa et al. · Oncogene · 2018 · 43 citations

Cancer Research, Receptor Tyrosine, Cell Regulation +11